Report Library
All Reports
Major Mergers and Acquisitions Analysis - Highlights from Q1 2019
June 04, 2019
Biopharma industry merger and acquisition dollars increased exponentially during the first quarter of 2019, with a $92bn total that
outperformed Q4 2018 almost nine times over. Unlike the previous quarter, which had just three transactions reaching the
billion dollar mark, Q1 2019 featured five deals exceeding this threshold. In this report, the Strategic Transactions and Biomedtracker
analysts highlight three major acquisitions that occurred in Q1 2019 through SWOT profiles.
To view the full report, download the PDF at the top of this page.
Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.
For our disclosures, please read the Biomedtracker Research Standards.
To view the full report, download the PDF at the top of this page.
Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.
For our disclosures, please read the Biomedtracker Research Standards.
| Disease Group Covered: |
Autoimmune/immunology
Hematology Neurology Oncology Ophthalmology |
| Indications Covered: |
Ischemic Stroke
Premenstrual Dysphoric Disorder (PMDD) Sleep Apnea Smoking Cessation Wound Healing |
Additional Resources:
- Key Potential Drug Launches in 2020
- 2019 Biomedtracker / Datamonitor Healthcare ASCO Weekend Update
- Bladder Cancer KOL Interview – US
- 2019 Biomedtracker / Datamonitor Healthcare Post-AAN Report
- 2019 Biomedtracker / Datamonitor Healthcare Pre-ASCO Podcast
- Datamonitor Healthcare Biosimilars Insights: Biosimilar Commercial Strategies and Tactics